机构:[1]Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[2]Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Sacramento, CA, USA[3]Institute for Regenerative Medicine and Stem Cell Research, Stanford University, Stanford, CA, USA[4]Department of Surgery, School of Medicine, University of California, Sacramento, CA, USA[5]Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Sacramento, CA, USA[6]Department of Thyroid and Breast Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China
Thyroid cancer (TC) is the most common endocrine malignancy, with high incidence rates in recent decades. Most TC cases have good prognoses, but a high risk of recurrence and metastases poses challenges, especially for patients with high-risk factors. Currently used prognostic markers for TC involve a combination of genetic factors and overexpressed proteins. Long non-coding RNAs (lncRNAs) regulate several integral biologic processes by playing key roles in the transcription of several downstream targets maintaining cellular behavior. Prior studies have revealed that lncRNAs promote tumor cell proliferation, invasion, metastasis, and angiogenesis, making them important targets for therapeutic intervention in cancer. While the exact molecular mechanisms underlying the role of lncRNAs in modulating TC progression and recurrence is still unclear, it is important to note that some lncRNAs are upregulated in certain cancers, while others are downregulated. In the present study, we review several key lncRNAs, their association with cancer progression, and the important roles they may play as tumor suppressors or tumor promoters in tumorigenesis. We discuss the potential mechanisms of lncRNA-mediated pathogenesis that can be targeted for the treatment of TC, the existing and potential benefits of using lncRNAs as diagnostic and prognostic measures for cancer detection, and tumor burden in patients.
2021 Annals of Translational Medicine. All rights reserved.
基金:
The present study was funded by West China Hospital, Sichuan University (No. ZY2017309).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|4 区医学
小类|4 区肿瘤学4 区医学:研究与实验
最新[2023]版:
无
第一作者:
第一作者机构:[1]Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, China
通讯作者:
通讯机构:[1]Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, China[*1]Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu 610041, China
推荐引用方式(GB/T 7714):
Zhao Hongyuan,De Souza Cristabelle,Kumar Vigneshwari Easwar,et al.Long non-coding RNA signatures as predictors of prognosis in thyroid cancer: a narrative review.[J].Annals of translational medicine.2021,9(4):359.doi:10.21037/atm-20-8191.
APA:
Zhao Hongyuan,De Souza Cristabelle,Kumar Vigneshwari Easwar,Nambiar Roshni,Hao Dake...&Zhu Jingqiang.(2021).Long non-coding RNA signatures as predictors of prognosis in thyroid cancer: a narrative review..Annals of translational medicine,9,(4)
MLA:
Zhao Hongyuan,et al."Long non-coding RNA signatures as predictors of prognosis in thyroid cancer: a narrative review.".Annals of translational medicine 9..4(2021):359